Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12597250 | 0.87 | LIPG (0.45) | LIPGMTNR1AMTNR1BSMN1; SMN2APLNR | |
| SCHEMBL12940754 | 0.80 | LIPG (0.48) | LIPG | |
| SCHEMBL12941831 | 0.79 | MTNR1A (0.41) | HDAC1MTNR1AMTNR1BSMN1; SMN2APLNR | |
| SCHEMBL12940916 | 0.78 | LIPG (0.41) | LIPG | |
| SCHEMBL12597728 | 0.77 | LIPG (0.74) | LIPGHDAC1HDAC2 | |
| SCHEMBL12967557 | 0.76 | HDAC1 (0.45) | HDAC1HDAC2SMN1; SMN2BACE1LMNA | |
| SCHEMBL24745514 | 0.73 | MTNR1A (0.41) | MTNR1AMTNR1BRXFP1 | |
| SCHEMBL30121847 | 0.73 | MTNR1A (0.41) | MTNR1AMTNR1BRXFP1 | |
| SCHEMBL24745431 | 0.71 | MTNR1A (0.41) | MTNR1AMTNR1BSMN1; SMN2LMNARXFP1 | |
| SCHEMBL12596664 | 0.70 | LIPG (0.45) | LIPGMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2514749-B1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2015-02-25 | — | — | EP | disclosed |
| US-20140323722-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-10-30 | — | — | US | disclosed |
| US-8754113-B2 | Oxadiazole derivative having endothelial lipase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| US-8754113-B2 | Oxadiazole derivative having endothelial lipase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| EP-2514749-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | Shionogi & Co., Ltd. (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-20120253040-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120253040-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120253040-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | LIPG, LPL, CEL | LIPG 1/4885HDAC1 615/4885HDAC2 1522/4885 |
| US-20140323722-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | LIPG, CEL, LPL | LIPG 1/4885HDAC1 372/4885HDAC2 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.